Real-world use of cladribine tablets (Completion rates and treatment persistence) In patients with multiple sclerosis in England: the CLARENCE Study

被引：0
|
作者：
Brownlee, W. [1 ]
Amin, A. [2 ]
Ashton, L. [2 ]
Herbert, A. [2 ]
机构：
[1] UCL Inst Neurol, Queen Sq MS Ctr, London, England
[2] Merck Serono Ltd, Merck KGaA, Feltham, England
来源：
MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 3_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P762
引用
收藏
页码：666 / 667
页数：2
相关论文
共 50 条
  • [1] Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: The CLARENCE study
    Brownlee, Wallace
    Amin, Amerah
    Ashton, Luke
    Herbert, Alex
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 79
  • [2] Real-World Evidence With Five-Year Data (2017-2022) on the use of Cladribine Tablets in Patients With Multiple Sclerosis in England: An Updated Analysis From the CLARENCE Study
    Brownlee, Wallace
    Amin, Amerah
    Ashton, Luke
    Herbert, Alex
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 993 - 994
  • [3] A Multicenter Real-World Data of Cladribine Tablets in Patients with Multiple Sclerosis in Turkey
    Koseoglu, Mesrure
    Omerhoca, Sami
    Balci, Fatma Belgin
    Unal, Aysun
    Ozdemir, Zeynep
    Yuksel, Burcu
    Celik, Rabia Gokcen Gozubatik
    Toprak, Ufuk Emre
    Gursoy, Esra Azize
    Icen, Nilufer Kale
    Altunrende, Burcu
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 1017 - 1017
  • [4] Real-World Outcomes With Cladribine Tablets in People With Relapsing Multiple Sclerosis
    Okuda, Darin
    Livingston, Terrie
    Moog, Tatum
    Smith, Alexander
    Lebson, Lori
    Piette, Elizabeth
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 1100 - 1100
  • [5] Cladribine tablets in people with relapsing multiple sclerosis: a real-world multicentric, multinational study
    Adamec, I.
    Jakob, G. Brec
    Rajda, C.
    Drulovic, J.
    Radulovic, L.
    Kes, V. Basic
    Lazibat, I.
    Rimac, J.
    Cindric, I.
    Grzincic, T.
    Abicic, A.
    Barun, B.
    Gabelic, T.
    Gomezelj, S.
    Pekmezovic, T.
    Klivenyi, P.
    Skoric, M. Krbot
    Habek, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 180 - 180
  • [6] Immunological consequences of cladribine treatment in multiple sclerosis: A real-world study
    Rolfes, Leoni
    Pfeuffer, Steffen
    Huntemann, Niklas
    Schmidt, Mariella
    Su, Chuanxin
    Skuljec, Jelena
    Aslan, Derya
    Hackert, Jana
    Kleinschnitz, Konstanze
    Hagenacker, Tim
    Pawlitzki, Marc
    Ruck, Tobias
    Kleinschnitz, Christoph
    Meuth, Sven G.
    Pul, Refik
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 64
  • [7] Immunological consequences of cladribine treatment in multiple sclerosis: a real-world study
    Rolfes, L.
    Pfeuffer, S.
    Huntemann, N.
    Schmidt, M.
    Su, C.
    Skuljec, J.
    Aslan, D.
    Hackert, J.
    Kleinschnitz, K.
    Hagenacker, T.
    Pawlitzki, M.
    Ruck, T.
    Kleinschnitz, C.
    Meuth, S. G.
    Pul, R.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 332 - 333
  • [8] 5 YEARS OF REAL-WORLD DATA ON THE USE OF CLADRIBINE TABLETS FOR THE TREATMENTS OF MULTIPLE SCLEROSIS IN PORTUGAL
    Ribeiro, M.
    Pinto, D.
    VALUE IN HEALTH, 2023, 26 (12) : S16 - S16
  • [9] Real-World Treatment Patterns and Effectiveness of Cladribine Tablets in Patients with Relapsing Forms of Multiple Sclerosis in the United States
    Song, Y.
    Wang, Y.
    Wong, S. L.
    Yang, D.
    Sundar, M.
    Tundia, N.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 203 - 203
  • [10] Real-world treatment patterns and effectiveness of cladribine tablets in patients with relapsing forms of multiple sclerosis in the United States
    Song, Yan
    Wang, Yan
    Wong, Schiffon L.
    Yang, Danni
    Sundar, Manasvi
    Tundia, Namita
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 79
12345